JAK1 and non-small cell lung carcinoma: The study particularly highlighted the inhibition of SRC, STAT3, PIK3CA, MAPK1, EGFR, and JAK1 through molecular docking, which are key proteins involved in the EGFR Tyrosine Kinase Inhibitor Resistance pathway in NSCLC.